Search
Tolperisone
go.drugbank.com/drugs/DB06264InvestigationalTolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentr...
Shea butter
go.drugbank.com/drugs/DB14311ApprovedShea butter is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Dark Spot Remover, Dark spot correctorAcemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigationalAcemetacin is a carboxymethyl ester of indometacin. It is a potent non-steroidal anti-inflammatory drug, derived from the indol-3-acetic acid, whose activity is thought to be mainly through its active metabolite indomethacin. In clinical...
Axomadol
go.drugbank.com/drugs/DB16100InvestigationalAxomadol is under investigation in clinical trial NCT01043263 (Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain).
Glycyrrhizic acid
go.drugbank.com/drugs/DB13751ApprovedInvestigationalGlycyrrhizic acid is extracted from the root of the licorice plant; Glycyrrhiza glabra. It is a triterpene glycoside with glycyrrhetinic acid that possesses a wide range of pharmacological and biological activities. When extracted from t...
Mixtures: Anti-Stretch MarkBrasofensine
go.drugbank.com/drugs/DB04857ExperimentalBrasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that ...
Artemisia tridentata pollen
go.drugbank.com/drugs/DB10390ApprovedArtemisia tridentata pollen is the pollen of the Artemisia tridentata plant. Artemisia tridentata pollen is mainly used in allergenic testing.
Mixtures: Sage Mix, Common/dark-leaved/dragon/pasture PollenLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cho...